INTERVIEW: Hilleman Seeks Hib Partners As It Hones Focus
This article was originally published in PharmAsia News
Executive Summary
Indian vaccine R&D firm Hilleman Laboratories says it's talking to potential partners about the clinical testing of a new "breakthrough" vaccine formulation that could create a far cheaper, more effective way to combat Haemophilus influenzae type b (Hib) and be in production in the next three to four years.